Literature DB >> 31049926

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

K Molloy1, C Jonak2, F J S H Woei-A-Jin3, E Guenova4, A M Busschots3, A Bervoets3, E Hauben3, R Knobler2, S Porkert2, C Fassnacht4, R Cowan5, E Papadavid6, M Beylot-Barry7, E Berti8, S Alberti Violetti8, T Estrach9, R Matin10, O Akilov11, L Vakeva12, M Prince13, A Bates14, M Bayne15, R Wachsmuch16, U Wehkamp17, M Marschalko18, O Servitje19, D Turner20, S Weatherhead21, M Wobser22, J A Sanches23, P McKay24, D Klemke25, C Peng1, A Howles1, J Yoo1, F Evison1, J Scarisbrick1.   

Abstract

BACKGROUND: Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common cutaneous T-cell lymphomas. MF/SS is accompanied by considerable morbidity from pain, itching and disfigurement. AIM: To identify factors associated with poorer health-related quality of life (HRQoL) in patients newly diagnosed with MF/SS.
METHODS: Patients enrolled into Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI; an international observational study in MF/SS) had their HRQoL assessed using the Skindex-29 questionnaire. Skindex-29 scores were analysed in relation to patient- and disease-specific characteristics.
RESULTS: The study population consisted of 237 patients [60·3% male; median age 60 years, (interquartile range 49-70)], of whom 179 had early MF and 58 had advanced MF/SS. In univariate analysis, HRQoL, as measured by Skindex-29, was worse in women, SS, late-stage MF, those with elevated lactate dehydrogenase, alopecia, high modified Severity Weighted Assessment Tool and confluent erythema. Linear regression models only identified female gender (β = 8·61; P = 0·003) and alopecia (β = 9·71, P = 0·02) as independent predictors of worse global HRQoL. Item-level analysis showed that the severe impairment in symptoms [odds ratio (OR) 2·14, 95% confidence interval (CI) 1·19-3·89] and emotions (OR 1·88, 95% CI 1·09-3·27) subscale scores seen in women was caused by more burning/stinging, pruritus, irritation and greater feelings of depression, shame, embarrassment and annoyance with their diagnosis of MF/SS.
CONCLUSIONS: HRQoL is significantly more impaired in newly diagnosed women with MF/SS and in those with alopecia. As Skindex-29 does not include existential questions on cancer, which may cause additional worry and distress, a comprehensive validated cutaneous T-cell lymphoma-specific questionnaire is urgently needed to more accurately assess disease-specific HRQoL in these patients. What's already known about this topic? Cross-sectional studies of mixed populations of known and newly diagnosed patients with mycosis fungoides (MF)/Sézary syndrome (SS) have shown significant impairment in health-related quality of life (HRQoL). Previous studies on assessing gender-specific differences in HRQoL in MF/SS are conflicting. More advanced-stage disease and pruritus is associated with poorer HRQoL in patients with MF/SS. What does this study add? This is the first prospective study to investigate HRQoL in a homogenous group of newly diagnosed patients with MF/SS. In patients newly diagnosed with MF/SS, HRQoL is worse in women and in those with alopecia and confluent erythema. MF/SS diagnosis has a multidimensional impact on patient HRQoL, including a large burden of cutaneous symptoms, as well as a negative impact on emotional well-being.
© 2019 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2019        PMID: 31049926     DOI: 10.1111/bjd.18089

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  24 in total

1.  Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study.

Authors:  Morgan Nguyen; Tessa LeWitt; Yanzhen Pang; Katherine Bagnowski; Maria L Espinosa; Jaehyuk Choi; Joan Guitart; Walter Liszewski; Xiaolong Alan Zhou
Journal:  Arch Dermatol Res       Date:  2022-06-06       Impact factor: 3.017

Review 2.  Cutaneous T cell lymphoma.

Authors:  Reinhard Dummer; Maarten H Vermeer; Julia J Scarisbrick; Youn H Kim; Connor Stonesifer; Cornelis P Tensen; Larisa J Geskin; Pietro Quaglino; Egle Ramelyte
Journal:  Nat Rev Dis Primers       Date:  2021-08-26       Impact factor: 52.329

Review 3.  [Quality of life of patients with mycosis fungoides and Sézary syndrome].

Authors:  Manuel Jäger; Deniz Özistanbullu; Claus-Detlev Klemke; Sabine Tratzmiller
Journal:  Dermatologie (Heidelb)       Date:  2022-09-08

4.  Mycosis fungoides and Sézary syndrome.

Authors:  Constanze Jonak; Julia Tittes; Patrick Manfred Brunner; Emmanuella Guenova
Journal:  J Dtsch Dermatol Ges       Date:  2021-09       Impact factor: 5.231

5.  Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study.

Authors:  M M Shinohara; H M Mahurin; E Tarabadkar; D S Hippe; K Lachance; E J Kim; E T Loggers
Journal:  Skin Health Dis       Date:  2021-05-15

6.  Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma.

Authors:  Jennifer A Salant; Niloufer Khan; Judith E Nelson; Moe Norton-Westbrook; Anjali V Desai
Journal:  J Palliat Med       Date:  2021-12-31       Impact factor: 2.947

7.  The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.

Authors:  Xochiquetzal U Martinez; Arnab Chowdhury; Tracey Stiller; Joycelynne Palmer; Matthew Loscalzo; Estella Barrios; Farah R Abdulla; Jasmine Zain; Steven T Rosen; Christiane Querfeld
Journal:  Support Care Cancer       Date:  2021-05-07       Impact factor: 3.603

8.  Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Authors:  P Quaglino; H M Prince; R Cowan; M Vermeer; E Papadavid; M Bagot; O Servitjie; E Berti; E Guenova; R Stadler; C Querfeld; A M Busschots; E Hodak; A Patsatsi; J Sanches; M Maule; J Yoo; M Kevin; P Fava; S Ribero; L Zocchi; M Rubatto; M T Fierro; U Wehkamp; M Marshalko; C Mitteldorf; O Akilov; P Ortiz-Romero; T Estrach; L Vakeva; P A Enz; M Wobser; M Bayne; C Jonak; M Rubeta; A Forbes; A Bates; M Battistella; R Amel-Kashipaz; B Vydianath; A Combalia; E Georgiou; E Hauben; E K Hong; M Jost; R Knobler; I Amitay-Laish; D Miyashiro; J Cury-Martins; X Martinez; C Muniesa; H Prag-Naveh; A Stratigos; V Nikolaou; K Quint; C Ram-Wolff; K Rieger; R Stranzenbach; Á Szepesi; S Alberti-Violetti; E Felicity; L Cerroni; W Kempf; S Whittaker; R Willemze; Y Kim; J J Scarisbrick
Journal:  Br J Dermatol       Date:  2021-02-18       Impact factor: 9.302

9.  Prospective observational trial of low-dose skin electron beam therapy in mycosis fungoides using a rotational technique.

Authors:  Neil B Newman; Chirayu G Patel; George X Ding; John A Zic; Jeffrey Zwerner; Evan C Osmundson; Austin N Kirschner
Journal:  J Am Acad Dermatol       Date:  2020-12-14       Impact factor: 15.487

Review 10.  Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.

Authors:  R Ottevanger; S van Beugen; A W M Evers; R Willemze; M H Vermeer; K D Quint
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-14       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.